At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
COCP Cocrystal Pharma, Inc.
Closed 01-08 16:00:00 EST
2.41
+0.15
+6.50%
盘后2.41
+0.000.00%
16:00 EST
High2.60
Low2.28
Vol60.85K
Open2.44
D1 Closing2.26
Amplitude14.16%
Mkt Cap24.49M
Tradable Cap16.88M
Total Shares10.17M
T/O149.98K
T/O Rate0.87%
Tradable Shares7.01M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections
Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug Cdi-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.